180 Life Sciences Corp.ATNF
| Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
---|
Net loss | 123,764 | 1 | -91,300 | -10,884,058 | -20,324,648 | -38,726,259 |
---|
Stock-based compensation | - | - | - | 1 | - | - |
---|
Shares issued for services | - | - | - | - | 2 | 331,591 |
---|
Amortization of stock options and restricted stock units | - | - | - | - | 3 | 3 |
---|
Impairment of goodwill | - | - | - | - | - | 34 |
---|
Impairment of IP R&D assets | - | - | - | - | - | 3 |
---|
Amortization of intangibles | - | - | - | - | 109,947 | 109,004 |
---|
Gain on settlement of liabilities, net | - | - | - | - | 926,829 | - |
---|
Loss on extinguishment of convertible note payable | - | - | - | - | 9,737 | - |
---|
Deferred tax liability | - | - | - | - | 24,803 | 942,749 |
---|
Offering costs allocated to warrant liabilities | - | - | - | - | 604,118 | - |
---|
Change in fair value of derivative liabilities | - | - | - | - | 5 | -15,144,986 |
---|
Change in fair value of accrued issuable equity | - | - | - | - | 9,405 | - |
---|
Prepaid expenses and other current assets | - | - | - | 210,195 | 1 | -1,018,303 |
---|
Accounts payable | - | - | - | 2 | -5,730,537 | 1 |
---|
Accrued expenses | - | - | - | -9,405 | -1,646,657 | 319,936 |
---|
Accrued expenses – related parties | - | - | - | - | - | 169,788 |
---|
Accrued issuable equity | - | - | - | - | 52,500 | - |
---|
Total adjustments | - | - | - | 8 | 953,220 | 27 |
---|
Net Cash Used In Operating Activities | -497,357 | -789,230 | -1,452,235 | -3,871,961 | -19,371,428 | -12,127,585 |
---|
Offering costs in connection with July 2022 sale of common stock and common stock warrants | - | - | - | - | - | -529,982 |
---|
Offering costs in connection with December 2022 sale of common stock and common stock warrants | - | - | - | - | -2,055,130 | -484,991 |
---|
Proceeds from loans payable | - | - | - | 82,500 | - | 1 |
---|
Repayment of convertible debt – related parties | - | - | 209,415 | - | 10,000 | - |
---|
Repayment of loans payable, net of adjustments (Note 9) | - | - | - | 72,843 | 807,594 | 2 |
---|
Repayment of loans payable – related parties | 61,558 | 200,000 | 100,000 | - | - | 81,277 |
---|
Proceeds from sale of July 2022 common stock and common stock warrants | - | - | - | 72,500 | 27 | 6 |
---|
Proceeds from sale of December 2022 common stock and common stock warrants | - | - | - | - | - | 6 |
---|
Proceeds from exercise of July 2022 pre-funded warrants | - | - | - | - | - | -263 |
---|
Proceeds from exercise of December 2022 pre-funded warrants | - | - | - | - | - | -150 |
---|
Net Cash Provided By Financing Activities | 117 | 156,844 | -106,508,638 | - | 25 | 11 |
---|
Effect of Exchange Rate Changes on Cash | - | - | - | - | - | -419 |
---|
Net (Decrease) Increase In Cash | - | - | - | - | 6 | -1,254,398 |
---|
Cash paid during the period for income taxes | 225,000 | - | - | - | - | - |
---|
Cash paid during the period for interest | - | - | - | - | 35,351 | 15,060 |
---|
Common stock issued upon conversion of KBL debt | - | - | - | - | 2 | - |
---|
Common stock issued upon conversion of 180 debt | - | - | - | - | 432,383 | - |
---|
Common stock issued in connection with repayment of related party loans and convertible notes | - | - | - | 223,710 | - | - |
---|
Shares and warrants issued for Alpha Settlement | - | - | - | - | 1 | - |
---|
Exchange of common stock equivalents for common stock | - | - | - | - | 146 | - |
---|
Shares issued to settle accounts payable | - | - | - | - | 2 | - |
---|
Reclassification of accrued issuable equity | - | - | - | - | 43,095 | - |
---|